Nanotechnology-based drug and gene delivery systems are emerging as vital tools for enhancing the treatment of difficult-to-manage diseases, such as cancer and pediatric HIV. These strategies offer controlled and targeted delivery to improve therapeutic outcomes, minimize toxicity, and enhance patient compliance. This seminar will cover several cutting-edge nanotechnology-driven approaches designed to address the challenges in treating these complex conditions.
Biography: Professor Shen’s research interests include formulation development and characterization, bioequivalence assessment strategies and in vitro-in vivo correlation (IVIVC) of complex dosage forms (such as nanocarriers, long-acting injectables/implants, and locally-acting dosage forms) for hard-to-treat diseases, including but not limited to, cancer, infectious diseases, substance use disorders, and eye diseases. Her team has also been focused on 3D printing and bioprinting for pharmaceutical applications. Professor Shen is currently serving as the Controlled Release Society (CRS) Diversified Products: Delivery Beyond Pharma (C&DP) Division and immediate-past Chair of the American Association of Pharmaceutical Scientists (AAPS) In Vitro Release and Dissolution Testing (IVRDT) Community.
Biography: Christian is a chemical/bioengineer progressively transformed into microbiologist, viral immunologist and vaccinologist. He is a recent PhD graduate from Monash University, Australia and holds a BSc (Hons) from KNUST, Ghana. During his PhD, he worked on “Engineering protein-based nanomaterials for biomedical applications (Antibacterials, multivalent therapeutics and vaccines)”.
After his PhD, Christian joined Prof Kizzmekia S. Corbett (COVID-19 Vaccine designer and Hero) as a Postdoctoral fellow and currently harnessing viral immunology, protein engineering and nanotechnology to inform novel universal vaccines and antibody therapeutics development to tackle coronaviruses and other emerging or re-emerging viruses with pandemic-threat all in the name of Endemic preparedness at Harvard University (Harvard T.H Chan School of Public Health and Department of Immunology and Infectious Diseases).